EIP have appointed IP lawyer Matthew Jones from Teva Pharmaceuticals Europe.
He is joining the firm’s London office as part of the IP litigation practice, EIP Legal, which is headed by Gary Moss. Matthew becomes EIP’s eighteenth partner and the fifth EIP Legal partner.
Matthew has extensive experience of handling large scale multi-jurisdictional patent litigation, including Generics [UK] Ltd v Yeda & Teva, which related to the blockbuster drug Copaxone®. He has acted in litigation relating to a wide range of technologies, including electronics, telecommunications, cryptography, optics and mechanical devices, and has particular experience in pharmaceuticals and biotechnology.
Partner Gary Moss said: “Matthew’s appointment further strengthens EIP’s offering in this discipline. Matthew and I worked together at McDermott Will & Emery and at Taylor Wessing. He is a highly experienced IP lawyer and his areas of technical expertise complement those of the current EIP Legal team. Coupled with our newly established office in the US and the future German office, this further strengthens our abilities to handle major litigation cases on a multi-jurisdictional basis.”
Matthew Jones said: “I am thrilled to be joining EIP which has demonstrated in the last few months its total commitment to large scale international IP Litigation. EIP’s virtually unique combination of IP Litigators and Patent and Trade Marks attorneys brings, I believe, significant advantages for clients in this area which I am eager to exploit. I am also very much looking forward to renewing my working relationship with Gary.”